Edison has issued research outlook on Tissue Regenix.
It says: "Tissue Regenix's (TRX) investment story is built on dCELL, a versatile regenerative medical technology and its potential applications across the subsectors: cardiac, wound care and orthopaedics.
"The cardiac division has a proven technology with the broadest clinical experience, with 10 years of clinical follow-up data recently presented. We maintain our sum-of-the-parts valuation at £338m.
"We recently revisited a number of our key valuation assumptions to reflect the clarity on launch timeframes, associated costs and updated revenue guidance. We maintain our DCF valuation at £338m or 44.4p per share.
"According to our model, the current price gives a free option on wound care, the most commercially advanced division, and does not reflect the full pipeline potential, which could ultimately be an acquisition target as a whole or by division."
The full report is available at: http://www.edisoninvestmentresearch.com/research/report/tissue-regenix5/preview/?utm_source=edison&utm_medium=rns_reach&utm_campaign=tissueregenix_15092016
At 3:19pm: (LON:TRX) Tissue Regenix Group PLC share price was +0.13p at 18.63p